SCHEMBL1642935

SCHEMBL1642935

O=C(O)CNC(=O)c1c(O)c(C(=O)NC2CCCCC2)cn(CC2CCCCC2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.48
BRD4 O60885 1/20 0.48
CNR1 P21554 8/20 0.45
CNR2 P34972 8/20 0.45
EGLN1 Q9GZT9 3/20 0.43
OGFOD1 Q8N543 1/20 0.43
EGLN2 Q96KS0 1/20 0.43
HIF1AN Q9NWT6 1/20 0.43
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HIF1A Q16665 1/20 0.40
BBOX1 O75936 1/20 0.40
ASPH Q12797 1/20 0.40
KDM8 Q8N371 1/20 0.40
HSD11B1 P28845 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
GAA P10253 1/20 0.39
PPARG P37231 1/20 0.39
NCOA2 Q15596 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641586 0.98 EGLN3 (0.48) EGLN3BRD4CNR1CNR2EGLN1
SCHEMBL1641249 0.86 EGLN3 (0.47) EGLN3CNR1CNR2EGLN1OGFOD1
SCHEMBL1642288 0.85 ALDH1A1 (0.46) EGLN3CNR1CNR2EGLN1OGFOD1
SCHEMBL1641918 0.85 EGLN3 (0.70) EGLN3BRD4CNR1CNR2
SCHEMBL1642795 0.84 EGLN3 (0.71) EGLN3BRD4CNR1CNR2EGLN1
SCHEMBL1641138 0.83 EGLN1 (0.50) EGLN3CNR1CNR2EGLN1OGFOD1
SCHEMBL1642747 0.83 EGLN1 (0.50) EGLN3CNR1CNR2EGLN1OGFOD1
SCHEMBL1642043 0.83 EGLN1 (0.47) EGLN3CNR1CNR2EGLN1OGFOD1
SCHEMBL1642791 0.83 EGLN1 (0.50) EGLN3CNR1CNR2EGLN1OGFOD1
SCHEMBL1641512 0.82 EGLN3 (0.53) EGLN3BRD4CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN3 3/4885BRD4 3195/4885CNR1 2636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.